Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
Bi Lian, Xiaosong Chen, Kunwei Shen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23

Showing 23 citing articles:

Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment
Linlin Zhou, Danny Yu
Pharmacological Research (2024) Vol. 204, pp. 107205-107205
Open Access | Times Cited: 9
Dietary modulation of epigenetics: Implications for cancer prevention and progression
Sirui Zhu, Xinyu Liang, Qian Bai, et al.
journal of nutritional oncology (2025)
Closed Access
A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors
Tanima Das, Sunandita Bhar, Diya Ghosh, et al.
Bioorganic Chemistry (2025) Vol. 156, pp. 108169-108169
Closed Access
At the nucleus of cancer: how the nuclear envelope controls tumor progression
Francesca Paganelli, Alessandro Poli, Serena Truocchio, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Stephen G. Smoots, Anna Schreiber, Marilyn M. Jackson, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 4
Beyond the Usual Suspects: Examining the Role of Understudied Histone Variants in Breast Cancer
Héjer Dhahri, Wesley N. Saintilnord, Darrell P. Chandler, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6788-6788
Open Access | Times Cited: 3
A network-based drug prioritization and combination analysis for the MEK5/ERK5 pathway in breast cancer
Regan Odongo, Asuman Demiroğlu-Zergeroğlu, Tunahan Çakır
BioData Mining (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials
Rama Rao Malla, Mundla Srilatha, Veda Muppala, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 707-720
Closed Access | Times Cited: 2
Crosstalk between SUMOylation and other post-translational modifications in breast cancer
Bajin Wei, Fan Yang, Luyang Yu, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects
Jiarui Hu, Siyu Fu, Zixuan Zhan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116109-116109
Closed Access | Times Cited: 6
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
Fernanda Cardoso da Silva, Douglas Cardoso Brandão, Everton Allan Ferreira, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1466-1466
Open Access | Times Cited: 5
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
M Bhat, Sonja Srdanović, Lotta‐Riina Sundberg, et al.
Drug Discovery Today (2024), pp. 104193-104193
Open Access | Times Cited: 1
The HDAC inhibitor HFY-4A improves TUSC2 transcription to induce immunogenic cell death in breast cancer
Yongshuo Yin, Xiao Guan, Genju Li, et al.
Toxicology and Applied Pharmacology (2023) Vol. 478, pp. 116698-116698
Closed Access | Times Cited: 4
Regulation of Hippo-YAP/CTGF signaling by combining an HDAC inhibitor and 5-fluorouracil in gastric cancer cells
Yanling Wu, Cong Shan Li, Ruo Yu Meng, et al.
Toxicology and Applied Pharmacology (2023) Vol. 482, pp. 116786-116786
Closed Access | Times Cited: 2
TSA attenuates the progression of c-Myc-driven hepatocarcinogenesis by pAKT-ADH4 pathway
Yang Liu, Juan Yu, Xiaotong An, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Enhancing MS‐275 Anticancer Activity: Encapsulation of MS‐275 in TPGS Micelles Demonstrated High Efficiency
Abdulelah Saleh Alshawli, Tarek A. Ahmed, Farid Ahmed, et al.
Journal of Nanotechnology (2024) Vol. 2024, Iss. 1
Open Access
From Biosensors to Robotics: Pioneering Advances in Breast Cancer Management
Mohd. Rahil Hasan, Mohd Mughees, Shifa Shaikh, et al.
Sensors (2024) Vol. 24, Iss. 18, pp. 6149-6149
Open Access
Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation
Hefeng Geng, Fang-Yuan Zheng, Wentao Sun, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113333-113333
Closed Access
Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis
Shule Fan, Zeyi Wan, Yuhua Qu, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 114, pp. 129986-129986
Closed Access
Mannose-6-Phosphate Isomerase Functional Status Shapes a Rearrangement in the Proteome and Degradome of Mannose-Treated Melanoma Cells
Nathália de Vasconcellos Racorti, M Martinelli, Silvina Odete Bustos, et al.
Journal of Proteome Research (2024) Vol. 23, Iss. 11, pp. 5177-5192
Open Access
Lysine deacetylase inhibitors have low selectivity in cells and exhibit predominantly off‐target effects
Kiara E. Bornes, M. D. Moody, Thomas M. Huckaba, et al.
FEBS Open Bio (2024) Vol. 15, Iss. 1, pp. 94-107
Open Access
A ACETILAÇÃO DAS HISTONAS E O PAPEL DAS HISTONAS DESACETILASES NO CÂNCER DE MAMA: UM OLHAR EPIGENÉTICO
Júlia Toneto Neves, Caio Effigen Bortolini, Davi Bonella Lopes, et al.
(2023), pp. 1-6
Open Access
Identifying candidate drugs based on transcriptional landscape associated with triple-negative breast cancer
Yuqin Lin, Yanghong Zhu, Xiang Li, et al.
Journal of Holistic Integrative Pharmacy (2023) Vol. 4, Iss. 4, pp. 318-324
Open Access
Page 1

Scroll to top